Previous 10 | Next 10 |
Gainers: Microvast Holdings ( MVST ) +19% . Hydrofarm Holdings Group ( HYFM ) +7% . Mammoth Energy Services ( TUSK ) +5% . Twist Bioscience ( TWST ) +5% . Certara ( CERT ) +5% . Losers: Bed Bath & Beyond ( BBBY ) ...
Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...
On May 18, I wrote the first of three articles stating that healthcare stocks, and specifically biopharmaceuticals, had likely bottomed. XBI was at 68 and IBB 114. Both XBI and IBB have increased since then. I viewed the valuations a few months ago as being compelling in several insta...
TWST reported its fiscal Q3 results highlighted by strong growth momentum. A new manufacturing facility set to launch in early 2023 is expected to more than double the current capacity. We like TWST as a category leader and see shares rallying higher supported by a positive long-t...
Shares of Twist Bioscience (NASDAQ: TWST) , a biotech company that makes synthetic DNA-based products, including synthetic genes, antibody libraries for drug development and tools for next-generation sample preparation, jumped 25.1% in July, according to according to data from S&a...
The following slide deck was published by Twist Bioscience Corporation in conjunction with their 2022 Q3 earnings call. For further details see: Twist Bioscience Corporation 2022 Q3 - Results - Earnings Call Presentation
Twist Bioscience press release ( NASDAQ: TWST ): FQ3 GAAP EPS of -$1.08 beats by $0.23 . Revenue of $56.11M (+60.2% Y/Y) beats by $4.05M . FY2022 Outlook : Revenue is now expected to be approximately $203M, an increase from previous guidance of $191M to $19...
-- Record revenue of $56.1M in 3QFY22; Increase of 60% over $35.0M in Fiscal 2021 -- -- Orders increased 53% in 3QFY22 over fiscal 2021 to $59.7M -- -- Increases revenue guidance to $203 million for full year fiscal 2022 -- Twist Bioscience Corporation (NASDAQ: TWST)...
Twist Bioscience ( NASDAQ: TWST ) is scheduled to announce Q2 earnings results on Friday, August 5th, before market open. The consensus EPS Estimate is -$1.31 (-67.9% Y/Y) and the consensus Revenue Estimate is $52.06M (+66.9% Y/Y). Over the last 2 years, TWST has bea...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at th...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...